SK Biopharmaceuticals Co. Ltd.'s three-pronged plan for tackling epilepsy is going strong, with lead drug cenobamate for drug-resistant focal-onset seizures nearing the finish line, and earlier-stage programs for a mRNA-based approach and a digital therapeutic in the works.
SK Biopharmaceuticals Co. Ltd. has launched a central nervous system-focused biotech company called Ignis Therapeutics Ltd. with a $180 million series A round led by 6 Dimensions Capital L.P. The financing of the new Shanghai-based company represents the largest series A investment in China’s biopharma industry in 2021, according to the two founding companies. KB Investment Co. Ltd, WTT investment Ltd., HBM Healthcare Investments AG and Goldman Sachs Group Inc. also participated in the round.
Higher antibody titer levels were found in participants receiving two doses of Moderna Inc.’s COVID-19 vaccine compared to those receiving the Pfizer Inc.-Biontech SE vaccine, according to a research letter published in JAMA.
HONG KONG – SK Biopharmaceuticals Co. Ltd. partner Arvelle Therapeutics GmbH, now part of Angelini Pharma, has received European Commission (EC) approval for Ontozry (cenobamate), a treatment for drug-resistant focal-onset seizures. The approval was granted for focal-onset seizures with or without secondary generalization in adults who have not been adequately controlled despite a history of treatment with at least two anti-epileptic medicines.
HONG KONG – Pangyo, South Korea-based SK Biopharmaceuticals Co. Ltd. has agreed to collaborate with New York-based Lifesci Venture Partners to invest in private health care companies developing novel therapies and innovative technologies.
HONG KONG – Pangyo, South Korea-based SK Biopharmaceuticals Co. Ltd. has agreed to collaborate with New York-based Lifesci Venture Partners to invest in private health care companies developing novel therapies and innovative technologies.
HONG KONG – SK Biopharmaceuticals Co Ltd.’s shares are still basking in the afterglow of a successful entrance on the Korea Exchange, which raised ?959.30 billion (US$799 million).
HONG KONG – SK Biopharmaceuticals Co Ltd.’s shares are still basking in the afterglow of a successful entrance on the Korea Exchange, which raised ?959.30 billion (US$799 million).
HONG KONG – South Korean conglomerate SK Group is preparing to list its subsidiary, SK Biopharmaceuticals Co. Ltd., on the Stock Market Division of the Korea Exchange.
On its PDUFA date Thursday, the FDA cleared Xcopri (cenobamate) tablets from South Korea’s SK Biopharmaceuticals Co. Ltd. to treat partial-onset seizures in adults. The drug’s mechanism of action is not fully understood, but it's believed to work through two separate mechanisms: enhancing inhibitory currents through positive modulation of GABA-A receptors and decreasing excitatory currents by inhibiting the persistent sodium current.
